609767-43-3

Usage

Chemical class

Quinazoline derivatives

Structure

Contains piperidine and quinazoline rings

Functional group

Ester with a tert-butyl group attached to the carboxylic acid moiety

Potential applications

Pharmaceutical, specifically in the treatment of cancer and inflammatory disorders

Interaction with biological systems

Possible interactions with receptors and enzymes

Need for further research

To determine specific pharmacological properties and therapeutic uses

Upstream product

• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 184475-71-6 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline 
• 574745-97-4 4-chloro-6-hydroxy-7-methoxyquinazoline 
• 612501-45-8 tert-butyl 4-((4-chloro-7-methoxy-quinazolin-6-yl)oxy)piperidine-1-carboxylate 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 

Downstream Products

• 609767-48-8 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-[(piperidin-4-yl)oxy]quinazoline 
• 1053775-58-8 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline 

Relevant academic research and scientific papers

Discovery of AZD8931, an equipotent, reversible inhibitor of signaling by EGFR, HER2, and HER3 receptors

Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers. Simultaneous, equipotent inhibition of EGFR-, HER2-, and HER3-mediated signaling may be of clinical utility in cancer settings where the selective EGFR or HER2 therapeutic agents are ineffective or only modestly active. We describe the discovery of AZD8931 (2), an equipotent, reversible inhibitor of EGFR-, HER2-, and HER3-mediated signaling and the structure-activity relationships within this series. Docking studies based on a model of the HER2 kinase domain helped rationalize the increased HER2 activity seen with the methyl acetamide side chain present in AZD8931. AZD8931 exhibited good pharmacokinetics in preclinical species and showed superior activity in the LoVo tumor growth efficacy model compared to close analogues. AZD8931 is currently being evaluated in human clinical trials for the treatment of cancer.

USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to the use of quinazoline derivatives, which show EGFR inhibitory activity, for the prevention and/or treatment of virus-induced diseases, preferably virus induced respiratory diseases and exacerbation in chronic airway diseases such as COPD or asthma.

Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics

The structure-activity and structure-property relationships of anilinoquinazoline inhibitors of EGFR were investigated. Strategies to lower volume of distribution and shorten half-life through structure and pKa modulation are discussed.